Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lyell Immunopharma, Inc. - Common Stock (NQ: LYEL )

0.4617 -0.0163 (-3.41%)
Streaming Delayed Price Updated: 3:10 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 319,815
Open 0.4828
Bid (Size) 0.4615 (3)
Ask (Size) 0.4618 (5)
Prev. Close 0.4780
Today's Range 0.4592 - 0.4900
52wk Range 0.3931 - 2.875
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma
From Lyell Immunopharma, Inc
Via GlobeNewswire
What's going on in today's session
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top gainers and losers in today's session. 
Via Chartmill

Performance

YTD
-28.42%
-28.42%
1 Month
-17.44%
-17.44%
3 Month
-19.77%
-19.77%
6 Month
-59.85%
-59.85%
1 Year
-81.08%
-81.08%

More News

Read More
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
The Analyst Verdict: Lyell Immunopharma In The Eyes Of 4 Experts
Via Benzinga
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Announces Participation in Upcoming Investor Conferences
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Completes Acquisition of ImmPACT Bio
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy
Via Benzinga
Why Deckers Outdoor Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Announces Participation in September Investor Conferences
From Lyell Immunopharma, Inc
Via GlobeNewswire
ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday
Via Benzinga
LYEL Stock Earnings: Lyell Immunopharma Beats EPS for Q2 2024
Via InvestorPlace
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024
From Lyell Immunopharma, Inc
Via GlobeNewswire
3 Biotech Stocks to Sell in August Before They Crash & Burn
Via InvestorPlace
Lyell Immunopharma Shares Plunge On One Patient Death In CAR-T Cell Therapy Cancer Trial
Via Benzinga
Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
From Lyell Immunopharma, Inc
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.